With RCTs requiring cardiovascular outcome data for granting new diabetic medications, GLP-1 analogs were shown to have reduced major adverse cardiovascular events (MACE) in T2DM patients [11], [12]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.